<h3>Objective:</h3> To determine how environmental exposures prior to development of Parkinson’s disease (PD) relate to symptom progression in early disease. <h3>Background:</h3> The variability of symptom progression in people with PD (PwPD) is still largely unexplained. Specific environmental exposures have been associated with risk of PD and may predispose people to faster progression once disease develops. <h3>Design/Methods:</h3> PwPD in Fox Insight (FI) – an online, longitudinal study – reported various environmental exposures on the PD Risk Factor Questionnaire. We examined occupational pesticide exposure prior to PD diagnosis and head injury ≥5 years prior to PD diagnosis (HI). Severe HI was defined as HI complicated by fracture, seizure, or loss of consciousness. We limited analysis to PwPD who enrolled within two years of PD diagnosis and answered questionnaires at enrollment, 12 (±3) months, and 24 (±3) months. We used Cox proportional hazard models to compare time from diagnosis to development of (a) the need for assistance with walking (according to the MDS-UPDRS II) and (b) self-reported cognitive impairment (a score of ≤49 on the Penn Daily Activities Questionnaire [PDAQ]) between PwPD with and without exposure, adjusting for enrollment age, sex, and education (for PDAQ). Data were censored at 27 months of follow up. <h3>Results:</h3> 521 of 2,600 (20%) PwPD reported pesticide exposure before PD diagnosis. 1,065 of 3,278 (32%) reported HI ≥5 years before PD diagnosis. Pesticide exposure predicted faster progression to balance problems (aHR:2.29, 1.09–4.83, p=0.029) and to cognitive impairment (aHR:1.89, 1.05–3.41, p=0.034). Severe HI predicted faster progression to cognitive problems (aHR:1.93, 1.04–3.61, p=0.038). Exposure to both pesticides and HI was associated with faster progression of cognitive problems than either alone (aHR:2.57, 1.05–6.31, p=0.039). <h3>Conclusions:</h3> Occupational pesticide exposure or HI prior to PD diagnosis may cause a faster progression of motor and cognitive symptoms once PD develops. <b>Disclosure:</b> Dr. Brown has received personal compensation in the range of $0-$499 for serving as a Consultant for Rune Labs, Inc. Dr. Brown has received personal compensation in the range of $0-$499 for serving as a Consultant for Oscar Health. Dr. Brown has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NEJM Knowledge Plus. The institution of Dr. Brown has received research support from Michael J. Fox Foundation. The institution of Dr. Brown has received research support from NIH. The institution of Dr. Brown has received research support from Biogen Inc. Dr. Goldman has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Littlepage Booth Leckman. The institution of Dr. Goldman has received research support from Michael J Fox Foundation. The institution of Dr. Goldman has received research support from US Department of Defense. The institution of Dr. Goldman has received research support from US Veterans Administration. The institution of Dr. Goldman has received research support from National Institutes of Health. The institution of Dr. Goldman has received research support from Health Resources and Services Administration. The institution of Dr. Goldman has received research support from American Academy of Pediatrics. Dr. Goldman has received personal compensation in the range of $100,000-$499,999 for serving as a Professor with University of California San Francisco. Dr. Goldman has received personal compensation in the range of $100,000-$499,999 for serving as a Staff Physician with San Francisco Veterans Affairs Health Care System. Dr. San Luciano has received research support from NIH (NINDS). Ms. Korell has nothing to disclose. Dr. Tanner has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for CNS Ratings . Dr. Tanner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cadent . Dr. Tanner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Adamas . Dr. Tanner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Tanner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kyowa Kirin. Dr. Tanner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Parkinson Study Group (Biogen). Dr. Tanner has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Acorda. Dr. Tanner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jazz Pharmaceuticals/Cavion. The institution of Dr. Tanner has received research support from Gateway LLC. The institution of Dr. Tanner has received research support from Roche\Genentech. The institution of Dr. Tanner has received research support from BioElectron Technology Corporation . The institution of Dr. Tanner has received research support from Biogen Idec . The institution of Dr. Tanner has received research support from Michael J Fox Foundation . The institution of Dr. Tanner has received research support from Parkinson Foundation . The institution of Dr. Tanner has received research support from National Institute of Health . The institution of Dr. Tanner has received research support from Department of Defense. Dr. Tanner has received personal compensation in the range of $5,000-$9,999 for serving as a Scientific Advisor with Australian Parkinson’s Mission .